End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
24.92 USD | +5.19% | -2.39% | +139.62% |
06-27 | Cantor Fitzgerald Initiates Dianthus Therapeutics at Overweight | MT |
06-12 | Dianthus Therapeutics Secures US FDA Approval to Launch Phase 2 Study of DNTH103 in Multifocal Motor Neuropathy | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+139.62% | 760M | |
+15.20% | 121B | |
+19.67% | 113B | |
+18.95% | 26.02B | |
-23.86% | 19.39B | |
-19.03% | 15.91B | |
-20.90% | 15.09B | |
-46.14% | 15.06B | |
+63.85% | 14.93B | |
+4.49% | 13.85B |
- Stock Market
- Equities
- DNTH Stock
- News Dianthus Therapeutics, Inc.
- Cantor Fitzgerald Initiates Dianthus Therapeutics at Overweight